Patienter med stigning i leverenzymer under behandling med anidulafungin, bør monitoreres for tegn på forværring af leverfunktionen, og risk/ benefit- forholdet ved fortsat anidulafungin- behandling bør vurderes.
Patients with increased hepatic enzymes during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/ benefit of continuing anidulafungin therapy.